Ovarian cancer is a malignant tumor that develops in the ovarian tissue. Approximately 90% to 95% of ovarian cancers are primary, meaning they form within the ovaries, while the remaining 5% to 10% are metastatic cancers that have spread to the ovaries from other sites. Early-stage ovarian cancer typically presents with no distinct symptoms, and even when symptoms are present, they lack specificity, making early diagnosis relatively challenging. About 60% to 70% of patients are diagnosed at an advanced stage with poor treatment outcomes. Although the occurrence of ovarian cancer is lower than that of cervical and endometrial cancers, its mortality rate is much higher. Ovarian cancer ranks as the leading cause of mortality among malignant tumors of the female reproductive tract, and mortality rate has been on the rise, posing a significant threat to women's health. Effectively improving the survival period of ovarian cancer patients has become a pressing challenge.

In recent years, there has been remarkable progress in the development of molecular targeted therapies. It’s shown that targeted drugs for the ovarian cancer play a significant role in enhancing patient survival. The development of targeted therapies has brought hope to ovarian cancer patients, offering them more effective treatment strategies.

The TargetMol anti-ovarian cancer compound library comprises a collection of Xnum compounds, including compounds reported to exhibit therapeutic effects against ovarian cancer as well as compounds with the potential for treating ovarian cancer. The library serves as a valuable tool for the research and development of anti-ovarian cancer drugs.